AKT1 and cancer: Targeting elements of the PI3K/AKT axis such as G3BP1, PI3Kβ, or mutant PIK3CA can restore antitumor immunity and improve responsiveness to immune checkpoint inhibitors, offering promising strategies for treating cancers.